Meeting
2020 Genitourinary Cancers Symposium
Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, survival, and late toxicity outcomes.
Authors
Andrew Loblaw
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Andrew Loblaw , Bindu Musunuru , Patrick Cheung , Danny Vesprini , Stanley K. Liu , William Chu , Hans T. Chung , Gerard Morton , Andrea Deabreu , Melanie Davidson , Ananth Ravi , Joelle Helou , Ling Ho , Liying Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
12345678
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 328)
Abstract #
328
Poster Bd #
M12
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Long-term treatment outcomes from the International Multi-Institutional Stereotactic Body Radiation Therapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium.
First Author: Luca Faustino Valle
Poster
2019 Genitourinary Cancers Symposium
Multi-institutional analysis of high-risk prostate cancer patients treated with stereotactic body radiotherapy.
First Author: Naomi Y Jiang
Poster
2017 Genitourinary Cancers Symposium
Pelvic SABR with HDR boost in intermediate- and high-risk prostate cancer (SPARE): Favorable early toxicity and quality-of-life outcomes.
First Author: Hima Bindu Musunuru
Poster
2018 Genitourinary Cancers Symposium
Long-term outcomes of stereotactic body radiotherapy for low- and intermediate-risk prostate adenocarcinoma: A multi-institutional consortium study.
First Author: Amar Upadhyaya Kishan